Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDxHealth SA ADR (MDXH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: MDXH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.55
1 Year Target Price $5.55
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.22% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 107.90M USD | Price to earnings Ratio - | 1Y Target Price 5.55 |
Price to earnings Ratio - | 1Y Target Price 5.55 | ||
Volume (30-day avg) 6 | Beta -490677.56 | 52 Weeks Range 1.35 - 3.50 | Updated Date 07/12/2025 |
52 Weeks Range 1.35 - 3.50 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -41.02% | Operating Margin (TTM) -18.89% |
Management Effectiveness
Return on Assets (TTM) -9.57% | Return on Equity (TTM) -1552.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 126210188 | Price to Sales(TTM) 1.14 |
Enterprise Value 126210188 | Price to Sales(TTM) 1.14 | ||
Enterprise Value to Revenue 1.34 | Enterprise Value to EBITDA -2.73 | Shares Outstanding 49497300 | Shares Floating 35018869 |
Shares Outstanding 49497300 | Shares Floating 35018869 | ||
Percent Insiders 13.22 | Percent Institutions 43.04 |
Upturn AI SWOT
MDxHealth SA ADR
Company Overview
History and Background
MDxHealth SA ADR (MDXH) is a molecular diagnostics company that provides actionable epigenetic information to personalize cancer treatment. Founded in 2003 in Belgium, it has focused on developing and commercializing tests for prostate cancer diagnosis and management. The company went public via ADR in the United States to expand its reach and investor base.
Core Business Areas
- Prostate Cancer Diagnostics: Development and commercialization of SelectMDx and ConfirmMDx tests for prostate cancer diagnosis and management. These tests utilize epigenetic markers to assess a patient's risk of having clinically significant prostate cancer.
Leadership and Structure
The leadership team consists of key executives overseeing operations, finance, and research & development. The organizational structure includes departments focused on commercial operations, research, and regulatory affairs.
Top Products and Market Share
Key Offerings
- SelectMDx: A urine-based molecular test that helps determine the risk of high-grade prostate cancer. It avoids unnecessary biopsies. Competitors include Exact Sciences' Oncotype DX Genomic Prostate Score and Myriad Genetics' Prolaris.
- ConfirmMDx: A tissue-based epigenetic test to assess the likelihood of cancer being present when a prior biopsy was negative but suspicion remains. Competitors include Exact Sciences' Oncotype DX Genomic Prostate Score and Myriad Genetics' Prolaris.
Market Dynamics
Industry Overview
The molecular diagnostics industry is rapidly growing, driven by advancements in genomics and epigenetics. The demand for personalized medicine and non-invasive diagnostic tools is increasing. Prostate cancer diagnostics represents a significant market segment.
Positioning
MDxHealth is positioned as a provider of epigenetic-based molecular diagnostic tests for prostate cancer, differentiating itself from competitors that primarily focus on genomic markers. The company has carved a niche by offering tests that provide actionable insights for urologists and patients.
Total Addressable Market (TAM)
The prostate cancer diagnostics market is estimated to be several billion dollars globally. MDxHealth aims to capture a significant portion of this TAM by leveraging its proprietary epigenetic technology and commercial partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary epigenetic technology
- Established commercial infrastructure
- Growing adoption of SelectMDx and ConfirmMDx tests
- Clear focus on prostate cancer diagnostics
Weaknesses
- Reliance on a single therapeutic area
- Competition from larger, more established diagnostic companies
- Need for continued investment in research and development
- Reimbursement challenges
Opportunities
- Expanding applications of epigenetic technology to other cancers
- Strategic partnerships with pharmaceutical companies
- Increased awareness and adoption of molecular diagnostics
- Geographic expansion
Threats
- Changes in reimbursement policies
- Emergence of new diagnostic technologies
- Competition from existing market players
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- EXAS
- MYGN
Competitive Landscape
MDxHealth competes with larger, more established diagnostic companies such as Exact Sciences and Myriad Genetics. MDxHealth differentiates itself through its focus on epigenetic markers and its specific tests for prostate cancer diagnosis.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased adoption of SelectMDx and ConfirmMDx tests. N/A Data
Future Projections: Future growth is projected to be driven by expanding market share, strategic partnerships, and new product development. N/A Data
Recent Initiatives: Recent initiatives include expanding the commercial team, launching new marketing campaigns, and pursuing strategic partnerships.
Summary
MDxHealth, MDXH, is a specialized molecular diagnostic company focused on prostate cancer. Their epigenetic-based tests offer a unique advantage, contributing to revenue growth. The company faces competition from larger players and needs to manage reimbursement risks. Strategic partnerships and geographic expansion are crucial for future success and profitability. Continued investment in R&D will also be necessary to ensure their continued leadership.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MDxHealth SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-04 | CEO & Executive Director Mr. Michael K. McGarrity | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 312 | Website https://mdxhealth.com |
Full time employees 312 | Website https://mdxhealth.com | ||
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It also offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.